Abstract
The COVID-19 reality challenged the assumption underlying Articles31-31bisof the TRIPS agreement. It illustrated that the major obstacle to access of developing countries and LDCs to medicines and/or vaccines in cases of broad-scale, global pandemics is global production capacity and distribution priorities, namely: availability, rather than price. This article examines the future implications of this understanding.
Highlights
Original PaperAdvances in Politics and Economics ISSN 2576-1382 (Print) ISSN 2576-1390 (Online). Nellie Munin1* 1 The law school, Zefat Academic College, Israel * Nellie Munin, The law school, Zefat Academic College, Israel
Patent rights ensure exclusive developers’ rights for royalties on new medicines and/or vaccines
It illustrated that the major obstacle to access of developing countries and least developed countries (LDCs) to medicines and/or vaccines in cases of broad-scale, global pandemics is global production capacity and distribution priorities, namely: availability, rather than price
Summary
Advances in Politics and Economics ISSN 2576-1382 (Print) ISSN 2576-1390 (Online). Nellie Munin1* 1 The law school, Zefat Academic College, Israel * Nellie Munin, The law school, Zefat Academic College, Israel.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
